Disease management interventions for improving self-management in lower-limb peripheral arterial disease

Revascularization for Lower Limb Peripheral Arterial Disease

Lipid-lowering for peripheral arterial disease of the lower limb.

BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease. It may also reduce cardiovascular events and/or local disease progression in people with lower limb peripheral arterial disease (PAD). OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality, cardiovascular events and local disease progression in patients...

Management of peripheral arterial disease of the lower extremities.

Smoking should be stopped and hypertension, diabetes mellitus, dyslipidemia, and hypothyroidism treated in patients with peripheral arterial disease (PAD) of the lower extremities. Statins decrease the incidence of intermittent claudication and improve exercise duration until the onset of intermittent claudication in persons with PAD and hypercholesterolemia. Antiplatelet drugs such as aspirin ...

Diagnosis and management of lower limb peripheral arterial disease: summary of NICE guidance.

Lower limb peripheral arterial disease (referred to as peripheral arterial disease in this summary) is common, affecting 3% to 7% of people in the general population and 20% of people over the age of 75. It is associated with an increased risk of cardiovascular morbidity and mortality and severely limits people’s functional capacity and quality of life. Peripheral arterial disease is often asym...

In Brief Management of Peripheral Arterial Disease

Peripheral arterial disease (PAD) is a common atherosclerotic disease affecting the quality of life of > 8 million Americans. PAD is characterized by atherosclerotic stenoses of arteries that supply the lower extremities and is associated with a marked increase in the short-term risk of heart attack, stroke, amputation, and death. Adherence to pharmacological therapies and modification of lifes...